143 related articles for article (PubMed ID: 23564779)
1. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma.
Innamaa A; Jackson L; Asher V; Van Shalkwyk G; Warren A; Hay D; Bali A; Sowter H; Khan R
Anticancer Res; 2013 Apr; 33(4):1401-8. PubMed ID: 23564779
[TBL] [Abstract][Full Text] [Related]
2. Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer.
Innamaa A; Jackson L; Asher V; van Schalkwyk G; Warren A; Keightley A; Hay D; Bali A; Sowter H; Khan R
Clin Transl Oncol; 2013 Nov; 15(11):910-8. PubMed ID: 23479219
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of galectin-7 in epithelial ovarian cancer.
Kim HJ; Jeon HK; Lee JK; Sung CO; Do IG; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
Anticancer Res; 2013 Apr; 33(4):1555-61. PubMed ID: 23564797
[TBL] [Abstract][Full Text] [Related]
4. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.
Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J
Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099
[TBL] [Abstract][Full Text] [Related]
5. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
6. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
7. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
8. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
9. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.
Fang Y; Li Z; Wang X; Zhang S
Tumour Biol; 2012 Dec; 33(6):2299-306. PubMed ID: 22923389
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
[TBL] [Abstract][Full Text] [Related]
11. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
Gu G; Chen Y; Duan C; Zhou L; Chen C; Chen J; Cheng J; Shi N; Jin Y; Xi Q; Zhong J
Oncol Rep; 2017 Mar; 37(3):1511-1520. PubMed ID: 28098897
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
14. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
15. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
[TBL] [Abstract][Full Text] [Related]
16. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
18. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
Davidson B; Alejandro E; Flørenes VA; Goderstad JM; Risberg B; Kristensen GB; Trope CG; Kohn EC
Cancer; 2004 May; 100(10):2139-47. PubMed ID: 15139056
[TBL] [Abstract][Full Text] [Related]
19. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
20. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
